-
31st World Muscle Society Congress: Duchenne and Becker Muscular Dystrophy Highlights
Duchenne muscular dystrophy research update Members of the CureDuchenne team recently attended the 31st World Muscle Society (WMS) Congress, where we spent a productive week connecting with researchers, clinicians, pharmaceutical companies, and patient advocacy organizations from around the world. Meetings and presentations throughout the conference provided valuable insights into the latest scientific advances and emerging treatments for…
-
Approved Duchenne gene therapy may be safe for boys as young as 2
The gene therapy Elevidys (delandistrogene moxeparvovec-rokl), approved in the U.S. to treat people ages 4 and older with Duchenne muscular dystrophy (DMD), can be safely administered to boys with DMD as young as 2 years old, new data show. A new analysis, which covered nine boys with DMD given the gene therapy at age 2,…








